Impact of neurotrophic factors combination therapy on retinitis pigmentosa

Yin, Xiaobei; He, Ting; Chen, Rui; Cui, Hui Song; Li, Genlin

doi:10.1177/0300060520967833

Cited by 4 publications

(3 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another aspect of cell-based therapies for RP involves promoting the survival and function of existing retinal cells. Various approaches, including the transplantation of supportive cells or the delivery of neurotrophic factors, are being explored to enhance survival and protect the remaining retinal cells from further degeneration [142]. The neuroprotection and cell survival enhancement in RP could be achieved through the administration of neurotrophic factors like brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and glial cell line-derived neurotrophic factor (GDNF) delivered to the retina with intravitreal injections where they promote the survival of retinal cells [143,144].…”

Section: Strategies For Promoting the Survival And Function Of Existi...mentioning

confidence: 99%

The New Era of Therapeutic Strategies for the Treatment of Retinitis Pigmentosa: A Narrative Review of Pathomolecular Mechanisms for the Development of Cell-Based Therapies

Becherucci,

Bacci,

Marziali

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Retinitis pigmentosa, defined more properly as cone–rod dystrophy, is a paradigm of inherited diffuse retinal dystrophies, one of the rare diseases with the highest prevalence in the worldwide population and one of the main causes of low vision in the pediatric and elderly age groups. Advancements in and the understanding of molecular biology and gene-editing technologies have raised interest in laying the foundation for new therapeutic strategies for rare diseases. As a consequence, new possibilities for clinicians and patients are arising due to the feasibility of treating such a devastating disorder, reducing its complications. The scope of this review focuses on the pathomolecular mechanisms underlying RP better to understand the prospects of its treatment using innovative approaches.

show abstract

Section: Strategies For Promoting the Survival And Function Of Existi...mentioning

confidence: 99%

The New Era of Therapeutic Strategies for the Treatment of Retinitis Pigmentosa: A Narrative Review of Pathomolecular Mechanisms for the Development of Cell-Based Therapies

Becherucci,

Bacci,

Marziali

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…To achieve greater therapeutic efficacies, it may also be necessary to combine different compounds that target multiple mechanisms of RGC loss ( Konstas et al, 2020 ). For instance, pharmacological approaches to reduce inflammation and oxidative stress in combination with gene therapy are currently being developed ( Katsu-Jiménez et al, 2016 ; Yin et al, 2020 ). Although the use of combination therapies has been recommended, there are still no reports on their clinical efficacy.…”

Section: Adjuvant Therapy To Boost Bdnf Signalingmentioning

confidence: 99%

Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in Glaucoma: A Review of Current State of the Art

et al. 2022

View full text Add to dashboard Cite

Retinal ganglion cells (RGCs) are neurons of the visual system that are responsible for transmitting signals from the retina to the brain via the optic nerve. Glaucoma is an optic neuropathy characterized by apoptotic loss of RGCs and degeneration of optic nerve fibers. Risk factors such as elevated intraocular pressure and vascular dysregulation trigger the injury that culminates in RGC apoptosis. In the event of injury, the survival of RGCs is facilitated by neurotrophic factors (NTFs), the most widely studied of which is brain-derived neurotrophic factor (BDNF). Its production is regulated locally in the retina, but transport of BDNF retrogradely from the brain to retina is also crucial. Not only that the interruption of this retrograde transport has been detected in the early stages of glaucoma, but significantly low levels of BDNF have also been detected in the sera and ocular fluids of glaucoma patients, supporting the notion that neurotrophic deprivation is a likely mechanism of glaucomatous optic neuropathy. Moreover, exogenous NTF including BDNF administration was shown reduce neuronal loss in animal models of various neurodegenerative diseases, indicating the possibility that exogenous BDNF may be a treatment option in glaucoma. Current literature provides an extensive insight not only into the sources, transport, and target sites of BDNF but also the intracellular signaling pathways, other pathways that influence BDNF signaling and a wide range of its functions. In this review, the authors discuss the neuroprotective role of BDNF in promoting the survival of RGCs and its possible application as a therapeutic tool to meet the challenges in glaucoma management. We also highlight the possibility of using BDNF as a biomarker in neurodegenerative disease such as glaucoma. Further we discuss the challenges and future strategies to explore the utility of BDNF in the management of glaucoma.

show abstract

“…Worthy of note, BDNF deficiency in different DR cell culture models was shown to contribute to abnormally increased autophagy [ 5 ], evidenced by enhanced microtubule-associated protein light chain 3 B (LC3B) expression [ 6 ]. This is a marker of autophagosome formation [ 7 ] strictly involved in the degradation of connexin 43 (Cnx43) [ 8 ], a gap junction reduced in DR and associated to retinal vascular cell death [ 9 , 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Systemic Beta-Hydroxybutyrate Affects BDNF and Autophagy into the Retina of Diabetic Mice

Trotta

Gesualdo

Herman

et al. 2022

IJMS

View full text Add to dashboard Cite

Background: Diabetic retinopathy (DR) is a neurovascular disease, characterized by a deficiency of brain-derived neurotrophic factor (BDNF), a regulator of autophagy. Beta-hydroxybutyrate (BHB), previously reported as a protective agent in DR, has been associated with BDNF promotion. Here, we investigated whether systemic BHB affects the retinal levels of BDNF and local autophagy in diabetic mice with retinopathy; Methods: C57BL/6J mice were administered with intraperitoneal (i.p.) streptozotocin (STZ) (75 mg/kg) injection to develop diabetes. After 2 weeks, they received i.p. injections of BHB (25–50–100 mg/kg) twice a week for 10 weeks. Retinal samples were collected in order to perform immunofluorescence, Western blotting, and ELISA analysis; Results: BHB 50 mg/kg and 100 mg/kg significantly improved retinal BDNF levels (p < 0.01) in diabetic mice. This improvement was negatively associated with autophagosome–lysosome formations (marked by LC3B and ATG14) and to higher levels of connexin 43 (p < 0.01), a marker of cell integrity. Moreover, BHB administration significantly reduced M1 microglial activation and autophagy (p < 0.01); Conclusions: The systemic administration of BHB in mice with DR improves the retinal levels of BDNF, with the consequent reduction of the abnormal microglial autophagy. This leads to retinal cell safety through connexin 43 restoration.

show abstract

Impact of neurotrophic factors combination therapy on retinitis pigmentosa

Cited by 4 publications

References 52 publications

The New Era of Therapeutic Strategies for the Treatment of Retinitis Pigmentosa: A Narrative Review of Pathomolecular Mechanisms for the Development of Cell-Based Therapies

The New Era of Therapeutic Strategies for the Treatment of Retinitis Pigmentosa: A Narrative Review of Pathomolecular Mechanisms for the Development of Cell-Based Therapies

Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in Glaucoma: A Review of Current State of the Art

Systemic Beta-Hydroxybutyrate Affects BDNF and Autophagy into the Retina of Diabetic Mice

Contact Info

Product

Resources

About